{"name":"Elliott Vichinsky","slug":"elliott-vichinsky","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1tdmtRMkNHM0J5R1lrVzBzT2cxT2huS1BScG95VWVnelpCbUpHeGhoNVdlMWJscDN4SlVWd3VHUmhXVEdhdFlaMzNLUkRTbkRYc1E3d1dKU2plejlSZ1RQSzliWU9BdE9QdVE?oc=5","date":"2024-07-22","type":"pipeline","source":"Wiley Online Library","summary":"Disease burden, management strategies, and unmet needs in α-thalassemia due to hemoglobin H disease - Wiley Online Library","headline":"Disease burden, management strategies, and unmet needs in α-thalassemia due to hemoglobin H disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9FaE9Eal9FanpBTnpRTG9YRTNRb3dXTEM1ZjN3X1hZMF9ja1hURGhjZW1ULTRpSzUyZHNwck5qYlVGRXotakJSLUh1Mjk3N0l1MEFrRXdhcXd3c1ZVelVrdg?oc=5","date":"2019-06-14","type":"trial","source":"NEJM","summary":"A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease - NEJM","headline":"A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2018-07-26","type":"trial","source":"Newswise","summary":"New Study Shows L-Glutamine Decreases Sickle Cell Pain Crises, Hospitalizations | Newswise - Newswise","headline":"New Study Shows L-Glutamine Decreases Sickle Cell Pain Crises, Hospitalizations | Newswise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNc2JINDBVU0ZfTDZyODNCMXhhY25JQ2Zzc1lBbU1sZ1Bwd193MGllNEtaOGdiV2pCNEphanBTTDY4NVlxa3JIOU5ocWV3OVBOVS1tSlA3TDlxekFhc3RtS2ZsRjNLZmZlY0Z5NXE4VHFRRDNnVGNlV0JLX1VBNk1Xalln?oc=5","date":"2015-03-30","type":"regulatory","source":"MultiVu","summary":"Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overload - MultiVu","headline":"Novartis announces FDA approval for JadenuTM to simplify treatment administration for patients with chronic iron overloa","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}